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 Blepharophimosis-ptosis-epicanthus inversus syndrome
(BPES, OMIM 110100) is a rare autosomal dominant disease
with a prevalence of about 1 in 50,000 [1]. Clinically, BPES
has been divided into two subsets depending on the associa-
tion of ocular malformation with (type I) or without (type II)
premature ovarian failure (POF) [2]. Genetically, however,
both types are caused by mutations in FOXL2, and a geno-
type-phenotype correlation has been described in some cases
[3,4].
The human FOXL2 gene (OMIM 605597), located at
3q23, is a member of winged/forkhead transcription factor gene
family [5]. This single-exon gene codes a protein with 376
residues, which consists of a DNA-binding forkhead domain
(resudes 52-152) and a polyalanine domain (residues 221-234)
[3,6,7]. A number of mutations in FOXL2 have been identi-
fied [8], including six novel mutations in the Chinese popula-
tion [9-11].
Here, we report four mutations identified in six Chinese
families with BPES. Two novel missense mutations were as-
sociated with BPES type II.
METHODS
Patients:  Thirteen probands with BPES from unrelated fami-
lies were collected from the Zhongshan Ophthalmic Center.
Informed consent conforming to the tenets of the Declaration
of Helsinki and following the Guidance of Sample Collection
of Human Genetic Diseases (863-Plan) by the Ministry of Pub-
lic Health of China was obtained from all participated indi-
viduals or their guardians prior to the study. The diagnosis of
BPES was based on criteria previously established [12] with
exclusion of microphthalmia.
Mutation Analysis:  Genomic DNA was prepared from
leucocytes of peripheral venous blood [13]. Amplification of
the genomic fragments encompassing FOXL2 coding regions
(NCBI human genome build 35.1, NC_000003 for gDNA,
NM_023067 for mRNA, and NP_075555 for protein) was
carried out by PCR using primers as follows: AF: 5'-CAG CGC
CTG GAG CGG AGA G-3', AR: 5'-CTT GCC GGG CTG
GAA GTG C-3', BF: 5'-GAC CCG GCC TGC GAA GAC A-
3', BR: 5'-GGC CGC GTG CAG ATG GTG T-3', CF: 5'-CGC
GGC CGC TGT GGT CAA G-3', CR: 5'-GCT GGC GGC
GGC GTC GTC-3'. The sizes of the amplified DNA fragments
are 545 bp, 517 bp, and 500 bp, respectively.
PCR amplification was carried out initially at 95 °C for 8
min, followed by 5 cycles at 94 °C for 40 s, at 68 °C for 40 s,
at 72 °C for 40 s, then 5 cycles at 94 °C for 40 s, at 66 °C for
40 s, at 72 °C for 40 s, and a further 30 cycles at 94 °C for 40
s, at 64 °C for 40 s, at 72 °C for 40 s, and finally an elongation
step at 72 °C for 5 min. Due to the high GC-rich nature of
FOXL2, an additional 10% dimethylsulfoxide and 10% glyc-
erol were added to the PCR mixture in order to successfully
amplify the genomic fragments.
Direct sequencing of the PCR products was performed
with an ABI BigDye Terminator Cycle Sequencing Kit v3.1
(ABI Applied Biosystem, Foster City, CA), using an ABI 3100
Genetic Analyzer. Sequencing results from patients as well as
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108the FOXL2 consensus sequences from the NCBI Human Ge-
nome Database (NC_000003) were imported into the
SeqManII program of the Lasergene package (DNAStar Inc.,
Madison, WI) and then aligned to identify variations. Each
mutation was confirmed by bidirectional sequencing. Muta-
tion description followed the nomenclature recommended by
the Human Genomic Variation Society (HGVS).
Any variation detected in FOXL2 was further evaluated
in available family members as well as in 100 normal controls
by heteroduplex-SSCP analysis as described previously [14].
Two additional pairs of primers were used for heteroduplex-
SSCP analysis. The sequence of these primers were: DF: 5'-
CCG TAA GCG GAC TCG TGC-3', DR: 5'- AGT AGT TGC
CCT TGC GCT C-3', EF: 5'- CGC ACT TCC AGC CCG GCA
A-3', and ER: 5'- TGT GTA CGG CCC GTA CGA-3'.
In addition, one variation of insertions with multiple nucle-
otides that was found in three families was further analyzed
by cloning sequencing. PCR products harboring this mutation
were subcloned to pMD18-T Simple Vector (TaKaRa BIO,
Japan) according to the manufacture’s instructions. Clones with
the mutant allele as well as the normal allele were selected by
using heteroduplex-SSCP analysis. Sequence of the cloned
fragment was identified by cycle sequencing as described
above. Mutations were confirmed by sequencing three posi-
tive clones from each family. One mutation, c.241T>C, was
further analyzed by PCR-RFLP analysis since the mutation
creates a new FOKI site.
RESULTS
 All patients demonstrated typical features of BPES, includ-
ing small palpebral fissures, ptosis of the eyelids, and epican-
thus inversus (Figure 1). Upon complete sequencing analysis
of FOXL2 for 13 probands with BPES, four heterozygous
mutations were found in six probands, including c.241T>C,
c.650C>G, c.804dupC, and c.672_701dup (Figure 2; Table
1). Of the four, c.241T>C and c.650C>G are novel. All four
heterozygous mutations were further detected by heterodu-
plex-SSCP analysis, and one (c.241T>C) was further detected
by FOKI digestion (Figure 3). These mutations were also
present in affected patients from corresponding families but
neither in unaffected individuals nor in 100 controls.
The c.241T>C (p.Tyr81His) mutation results in substitu-
tion of a charge-free tyrosine with a charge-positive basic hy-
drophilic histidine within the forkhead domain. The c.650C>G
(p.Ser217Cys) mutation is located immediately upstream of
the polyalanine domain. The tyrosine at position 81 and the
serine at position 217 are well conserved in FOXL2 by
ClustalW analysis of 11 orthologs from related vertebrate spe-
cies (Figure 4).
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Figure 1. Clinical phenotype of a Chinese patient with BPES.  A
photo of the eyelid area from a 40 years old man (III:1 from family E
in Figure 3) demonstrated typical phenotype of BPES. The horizon-
tal diameter of his cornea was 11.5 mm for both eyes. Ultrasound A-
scan recorded an axial length of 24.19 mm/OD and 24.43 mm/OS.
His refractive measurement was -3.00DCX180°/OD and -
4.50DCX180°/OS.
Figure 2. Sequencing re-
sults of the two novel
mutations in FOXL2.  Se-
quence chromatograms of
Family A (A) and family
B (B), and their corre-
sponding normal se-
quences. The underline
below each sequence
highlights the codon con-
taining the mutation.
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Figure 3. Pedigrees and heteroduplex-SSCP analysis.  Pedigrees of the different families (A, B, C, D, E, and F) are shown. Black filled
symbols indicated patients affected with BPES in each family. The “+/+” or “+/-” sign indicated individuals analyzed with normal sequences
or heterozygous mutation in FOXL2, respectively. The “M” under each lane indicated mutation, the “N” represented normal individuals, and
“N+M” represented a mixture of PCR products resulted from normal and mutant clones. In addition, results of FOKI digestion for family A
were present at the bottom of Figure 1A. The c.241T>C mutation in family A creates an additional FOKI site. By FOKI digestion of the 545
bp PCR product, normal allele yielded two fragments (340 bp and 205 bp), but the mutant allele yielded three fragments (275 bp, 205 bp, and
65 bp). Patients with the heterozygous c.241T>C mutation had four bands (only three bands were shown in the figure) as compared to normal
individuals with two bands.
TABLE 1. FOXL2 MUTATIONS DETECTED IN CHINESE PATIENTS WITH BPES
Subtypes of BPES in families C, D, and F are unknown, as there were no female patients (families C and F) or the female patients were too
young (family D, where the two female patients were only 4 or 2 years old, respectively).
110DISCUSSION
FOXL2 encodes a forkhead transcription factor containing a
forkhead domain for DNA-binding and a polyalanine domain
of uncertain function. Strong expression of FOXL2 has been
found in eyelids [3,15], developing periocular muscles, and
surrounding tissues [16,17]. Of the four mutations identified
in this study, the c.241T>C affected the forkhead domain, while
the other three (c.650C>G, c.804dupC, and c.672_701dup)
were located upstream, within, and downstream of the
polyalanine domain, respectively.
Missense mutations in FOXL2 reported so far usually oc-
curred at the forkhead domain [9,17-19], except two, such as
c.650C>T in a Belgian family [4] and c.644A>G in a five-
generation family from south-India [20]. The clinical subtypes
of the patients with the c.650C>T and c.644A>G mutations
were unknown. The novel c.650C>G (p. Ser217Cys) muta-
tion identified in Chinese family B occurred at the same site
as that found in the Belgian family, which is located immedi-
ately upstream of the polyalanine domain. The serine at posi-
tion 217 is well conserved in 11 orthologs (Figure 4). It has
been shown that mutations affecting the polyalanine domain
induce extensive nuclear and cytoplasmic protein aggregation
[21,22]. Missense changes have been suggested to act as null
allele leading to BPES phenotype due to haploinsufficiency
[4] or dominant-negative effect [20,23].
It has been suggested that FOXL2 mutations truncating
the protein led to BPES type I while those extending the mu-
tant protein were associated with type II [3,4]. However, in-
tra- and inter-family phenotypic variations have been found
[3,4,19,24,25] so that this genotype-phenotype correlation
might not be general [18,19,26]. The c.804dupC mutation has
been shown to cause both types of BPES [4,19,25], and the
c.672_701dup causing polyalanine expansion most likely leads
to BPES type II [19]. Missense mutations have been associ-
ated with both BPES type I [17] and II [3,19]. The patients
from families A and B in this study, with novel c.241T>C and
c.650C>G mutations, respectively, had type II BPES. The
c.650C>G mutation is the first mutation described that occurs
immediately upstream of the polyalanine domain and associ-
ated with type II BPES. This may raise a possibility that the
region containing the c.650C>G mutation is of importance
for FOXL2 function.
The c.672_701dup (p.Ala224_Ala234dup) was found in
families D, E, and F (Table 1), consistent with a mutation
hotspot. To check the origin of the c.672_701dup mutation in
three families (families D, E, and F in Figure 3), six SNPs
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Figure 4. Multiple alignment of 11 FOXL2 orthologs.  This demonstrated high conservation of residues involved by the p.Tyr81His and
p.Ser217Cys mutation. The resource for the 11 FOXL2 orthologs was as follows: human (Homo sapiens, NP_075555), mouse (Mus musculus,
NP_036150), pig (Sus scrofa, AAQ91845), rabbit (Oryctolagus cuniculus, AAQ91846), rat (Rattus norvegicus, XP_345976), mole vole
(Ellobius lutescens, AAV30684), cow (Bos taurus, NP_001026920), goat (Capra hircus, AAM52099), chicken (Gallus gallus, NP_001012630),
zebrafish (Danio rerio, XP_698915), and salmon trout (Oncorhynchus mykiss, AAS87040).
TABLE 2. RESULTS OF SNPS ANALYSIS OF THE THREE FAMILIES WITH THE C.672_701DUP MUTATION
The origin of the c.672_701dup mutation in family D is different from family E as they have different SNP at rs2291252. This mutation in
family F is a de novo event, although patient II:1 in family F shares the same haplogroup of the six SNPs with that of family D.
111(including rs13325788, rs2291252, rs28937885, rs7432551,
rs28937884, and rs11924939) were analyzed (Table 2). The
SNP at rs2291252 is different between patient II:1 from fam-
ily D and patient III:1 from family E, which may suggest a
different origin of the mutant allele. The mutation in family F
is most likely a de novo event as BPES was not present in the
patients’ parents although the SNPs in the patient II:1 in fam-
ily F were the same as that of II:1 in family D. It has been
reported that 30% of the FOXL2 mutations lead to polyalanine
expansion [19]. The c.672_701dup has been found in BPES
families of Caucasian [4,19,27,28] and Asian origin [10,29].
In summary, we identified two novel and two known mu-
tations in FOXL2 of six Chinese families with BPES. The two
novel mutations are the first reported instances that were as-
sociated with BPES type II. Our results expanded the spec-
trum of FOXL2 mutations and confirmed the mutation hotspot
in FOXL2.
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